AX-2025-020432
GHRP-6 · 5 mg declared · Zhuhai Kerui Biotechnology Co., Ltd. · lot KP-2503-L4599
- Report ID
- AX-2025-020432
- Compound
- GHRP-6
- Compound class
- Growth-hormone axis peptides
- Supplier
- KP — Zhuhai Kerui Biotechnology Co., Ltd.
- Batch / lot
- KP-2503-L4599
- Declared label claim
- 5mg
- Laboratory
- Kestrel Bioanalytical
- Assay date
- 30 Jul 2025
- Submitted
- 21 Aug 2025
- Quarter
- 2025-Q3
- Submitter
- k.lundgren
- Sample provenance
- Supplier-supplied
Results
Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 15 min gradient, 214 nm | 98.43 | % area | ≥ 99.0 | FAIL |
| Total impurities | RP-HPLC, sum of reported peaks | 1.57 | % area | ≤ 1.0 | FAIL |
| Largest single impurity | RP-HPLC — bis-oxidised Trp (+32 Da) | 1.03 | % area | ≤ 1.00 | FAIL |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 872.4446 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, unit resolution (single quadrupole) | 872.4553 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +12.3 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 90.43 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.01 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 5.70 | mg | 5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 5.074 | mg | 5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 101.5 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.37 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 4.52 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.68 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 4.66 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 15 min gradient | 4.46 | min | 4.56 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.23 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 53,391 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Trp]-epimer | 0.76 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | GHRP-6 — main peak | 4.46 | 4,784,003 | 98.43 | — |
| 2 | bis-oxidised Trp (+32 Da) | 4.17 | 50,061 | 1.03 | +31.990 |
| 3 | [D-Trp]-epimer | 4.40 | 11,665 | 0.24 | 0.000 |
| 4 | oxidised Trp (+16 Da) | 4.29 | 8,263 | 0.17 | +15.995 |
| 5 | des-Lys (−128 Da) | 4.35 | 6,318 | 0.13 | -128.095 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 2+ | 437.2296 | 437.2349 | 0.0053 | 52.2 |
| 1+ | 873.4519 | 873.4626 | 0.0107 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.37 |
| Counter-ion (acetate) | ion chromatography | 4.52 |
| Residual solvent + inorganic residue | estimated | 0.68 |
| Total peptide content | by difference | 90.43 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.0 | 98.43 | divergence +0.56 pp vs batch median |
| Total impurities (% area) | not stated | 1.57 | |
| Largest single impurity (% area) | not stated | 1.03 | |
| Water (%) | 2.7 | 4.37 | |
| Counter-ion (%) | 8.9 | 4.52 | |
| Peptide content (%w/w) | 87.8 | 90.43 | |
| Endotoxin (EU/mg) | 0.29 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Supplier-supplied
- Evidentiary weight
- Weaker evidence. Read with the caveat below.
- Chain of custody
- Supplier despatch → laboratory direct (courier, cold pack, 5 d) → assay. Submitter did not handle the vial.
- Assay date
- 30 Jul 2025
- Submitted to the index
- 21 Aug 2025
- Laboratory
- Kestrel Bioanalytical, Melbourne, Australia
- Method basis
- 15 min gradient · unit-resolution MS
- Verification status
- IDENTITY CONSISTENT
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot KP-2503-L4599 n=4
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-020433 | KP-2503-L4599 | Janoshik | 2025-Q3 | 98.45 | 3.62 | — | Supplier-supplied | 2 | FAIL |
| AX-2025-020434 | KP-2503-L4599 | Janoshik | 2025-Q3 | 98.81 | 3.78 | 89.5 | Supplier-supplied | 3 | FAIL |
| AX-2025-020435 | KP-2503-L4599 | Janoshik | 2025-Q3 | 98.08 | 3.76 | 89.8 | Buyer-sourced | 3 | FAIL |
Cross-sections
- All GHRP-6 records n=169
- All KP records n=364
- All Kestrel records n=404
- All 2025-Q3 records n=819
- GHRP-6 by supplier
- GHRP-6 impurity profile
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042290 | HJ | HJ-2603-R2258 | Janoshik | 2026-Q3 | 99.71 | 3.05 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042287 | HJ | HJ-2603-R2258 | VendorInvestigate | 2026-Q3 | 98.79 | 2.43 | 90.9 | Buyer-sourced | 2 | FAIL |
| AX-2026-042288 | HJ | HJ-2603-R2258 | Kestrel | 2026-Q3 | 99.93 | 2.82 | 92.8 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042289 | HJ | HJ-2603-R2258 | Janoshik | 2026-Q3 | 99.53 | 2.67 | 104.7 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042291 | HJ | HJ-2603-R2258 | Janoshik | 2026-Q3 | 99.60 | 2.94 | 101.3 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043560 | BCH | BCH-2603-Y7018 | Janoshik | 2026-Q2 | 99.25 | 5.25 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043564 | BCH | BCH-2603-Y7018 | Medutest | 2026-Q2 | 98.44 | 4.83 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-043562 | BCH | BCH-2603-Y7018 | PeptideMeter | 2026-Q2 | 98.57 | 4.52 | 97.9 | Supplier-supplied | 1 | FAIL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043029 | Retatrutide | KP-2607-H5219 | Medutest | 2026-Q3 | 95.45 | 5.71 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-043030 | Retatrutide | KP-2607-H5219 | Kestrel | 2026-Q3 | 95.97 | 6.95 | 97.1 | Supplier-supplied | 2 | FAIL |
| AX-2026-043106 | Tirzepatide | KP-2608-D5921 | PeptideMeter | 2026-Q3 | 98.90 | 5.45 | 105.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043108 | Tirzepatide | KP-2608-D5921 | Janoshik | 2026-Q3 | 99.70 | 5.45 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043039 | Retatrutide | KP-2607-H5219 | Janoshik | 2026-Q3 | 96.14 | 5.62 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-043100 | Tirzepatide | KP-2608-D5921 | VendorInvestigate | 2026-Q3 | 98.27 | 5.31 | 94.4 | Buyer-sourced | 2 | MARGINAL |
| AX-2026-043090 | Ipamorelin | KP-2606-D5887 | Janoshik | 2026-Q3 | 98.18 | 3.07 | 101.2 | Laboratory-retained | 1 | FAIL |
| AX-2026-043028 | Retatrutide | KP-2607-H5219 | Janoshik | 2026-Q3 | 96.52 | 6.09 | — | Supplier-supplied | 2 | MARGINAL |